Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference
May 07 2020 - 4:07PM
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company leveraging deep understanding of immunobiology to develop
novel products to treat severe autoimmune and inflammatory
disorders, today announced that Bruce Steel, Equillium’s chief
executive officer and Krishna Polu, M.D., chief medical officer,
will participate in a fireside discussion at 2020 RBC Capital
Markets Virtual Global Healthcare Conference on Wednesday, May 20,
2020.
Date: |
Wednesday, May
20, 2020 |
Time: |
3:05 PM Eastern Time | 12:05 PM Pacific Time |
Location: |
Virtual Webcast |
Live webcasts of both presentations will be
available under the “Investors” section of the Company’s website
at https://ir.equilliumbio.com/. Replays will be available for
30 days following each webcast.
About Equillium
Equillium is a clinical biotechnology company leveraging deep
understanding of immunobiology to develop novel products to treat
severe autoimmune and inflammatory disorders with high unmet
medical need.
Equillium’s initial product candidate, itolizumab (EQ001), is a
clinical-stage, first-in-class monoclonal antibody that selectively
targets the CD6-ALCAM pathway. This pathway plays a central role in
modulating the activity and trafficking of T cells that drive a
number of immuno-inflammatory diseases. Itolizumab is a
clinically-validated therapeutic that has demonstrated a favorable
safety and tolerability profile. Equillium acquired rights to
itolizumab through an exclusive partnership with Biocon
Limited. Equillium believes that itolizumab has the potential
to be a best-in-class disease modifying therapeutic and is
advancing itolizumab into clinical development in the following
severe immuno-inflammatory disorders: uncontrolled asthma, acute
graft-versus-host disease, and lupus nephritis. For more
information, visit www.equilliumbio.com.
Investor
Contact+1-858-412-5302ir@equilliumbio.com
Media ContactCammy DuongCanale
Communications+1-619-849-5389cammy@canalecomm.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Sep 2024 to Oct 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Oct 2023 to Oct 2024